Format

Send to

Choose Destination
See comment in PubMed Commons below
Leukemia. 2014 Jun;28(6):1289-98. doi: 10.1038/leu.2013.360. Epub 2013 Nov 27.

Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Author information

1
1] Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany [2] Department of Systems Biology, Technical University of Denmark (DTU), Lyngby, Denmark.
2
Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
3
1] Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany [2] Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
4
Internal Medicine III, University of Ulm, Ulm, Germany.
5
Department of Systems Biology, Technical University of Denmark (DTU), Lyngby, Denmark.

Abstract

Chronic lymphocytic leukemia (CLL) is an incurable malignancy of mature B cells. One of the major challenges in treatment of CLL is the achievement of a complete remission to prevent relapse of disease originating from cells within lymphoid tissues and subsequent chemoresistance. In search for novel drugs that target CLL cells in protective microenvironments, we performed a fungal extract screen using cocultures of primary CLL cells with bone marrow-derived stromal cells. A secondary metabolite produced by Penicillium aquamarinium was identified as Chaetoglobosin A (ChA), a member of the cytochalasan family that showed preferential induction of apoptosis in CLL cells, even under culture conditions that mimic lymphoid tissues. In vitro testing of 89 CLL cases revealed effective targeting of CLL cells by ChA, independent of bad prognosis characteristics, like 17p deletion or TP53 mutation. To provide insight into its mechanism of action, we showed that ChA targets filamentous actin in CLL cells and thereby induces cell-cycle arrest and inhibits membrane ruffling and cell migration. Our data further revealed that ChA prevents CLL cell activation and sensitizes them for treatment with PI3K and BTK inhibitors, suggesting this compound as a novel potential drug for CLL.

PMID:
24280868
DOI:
10.1038/leu.2013.360
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center